Generics Player ANI Pharmaceuticals Strengthens Rare Disease Segment With $380M Alimera Sciences Deal [Yahoo! Finance]
ANI Pharmaceuticals, Inc. (ANIP)
Last ani pharmaceuticals, inc. earnings: 2/27 08:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
anipharmaceuticals.com/investors_corporate_profile.php
Company Research
Source: Yahoo! Finance
non-tradable contingent value right (CVR) of up to $0.50 per share upon the achievement of certain net revenue targets in 2026 and 2027 ANI will also repay $72.5 million of Alimera debt. The transaction, which values Alimera at approximately $381 million in upfront consideration, has been approved by both the ANI and Alimera Boards of Directors and is expected to close late in the third quarter of 2024. Alimera's two commercial products include Iluvien (fluocinolone acetonide intravitreal implant 0.19mg) is indicated for diabetic macular edema in the U.S., Europe and the Middle East and chronic non-infectious uveitis affecting the posterior segment (NIU-PS) in Europe and the Middle East. Yutiq (fluocinolone acetonide intravitreal implant 0.18mg) is available in the U.S. only and is indicated for chronic NIU-PS. Nikhil Lalwani, President and CEO of ANI, stated, “We believe ANI's proven commercial execution capabilities can further unlock ILUVIEN and YUTIQ, two growing and d
Show less
Read more
Impact Snapshot
Event Time:
ANIP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANIP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANIP alerts
High impacting ANI Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ANIP
News
- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) had its price target raised by analysts at HC Wainwright from $87.00 to $94.00. They now have a "buy" rating on the stock.MarketBeat
- Alimera (ALIM) Rises on Merger Deal With ANI Pharmaceuticals [Yahoo! Finance]Yahoo! Finance
- Exclusive: Route raises $40 million Series C at a $1.4 billion valuation [Fortune]Fortune
- ANI Pharmaceuticals' CEO Nikhil Lalwani Named EY Entrepreneur Of The Year® 2024 New Jersey Award Winner [Yahoo! Finance]Yahoo! Finance
- ANI Pharmaceuticals’ CEO Nikhil Lalwani Named EY Entrepreneur Of The Year® 2024 New Jersey Award WinnerGlobeNewswire
ANIP
Earnings
- 5/10/24 - Beat
ANIP
Sec Filings
- 6/24/24 - Form 4
- 6/24/24 - Form 8-K
- 6/21/24 - Form 144
- ANIP's page on the SEC website